Purpose: To compare the therapeutic efficacy and safety of dorzolamide/timolol fixedcombination in newly diagnosed primary open angle glaucoma patients.
Glaucoma is a major public health issue as it is a leading cause of blindness and affects more than 60 million people worldwide. 1 Lowering intraocular pressure is the only established treatment for glaucoma. While the pendulum is swinging from medical treatment to minimally invasive glaucoma surgeries for mild to moderate glaucoma, medications are still first line therapy in the most practice settings. 2 The ideal medication regimen should address both peak and fluctuation characteristics of intraocular pressure profile. Typically, first line treatment involves monotherapy with prostaglandin analogues as they are more efficacious than any other single agent and yield flatter IOP-controlling pattern. 3 Meanwhile, fixed combination (FC) glaucoma medications are introduced to improve the outcome of medical therapy by boosting the compliance as well as efficacy. As such several ophthalmologists opted to use them as first line treatment to avoid ocular side effects of prostaglandin analogues. 4 Fixed combination of timolol 0.5% -dorzolamide 2.0% is the most frequently prescribed FC medication and perhaps the most studied one. 5 It is well established that it reduces IOP more than monotherapy of each agent alone and is as safe and effective as concomitant use of timolol and dorzolamide. 6, 7 In the lights of the results of Early Manifest Glaucoma Trial 8 that showed more IOP reduction in early glaucoma results in less disease progression as well as concerns regarding the diurnal IOP-controlling effects of fixed combination medications, some ophthalmologists started to schedule three-times a day Cosopt administration instead of advocated twice daily dosage . 9 Although increasing the dosage of timolol from twice to three times a day resulted in more IOP reduction in one study, concern remains regarding the systemic side effects, especially cardiovascular, of more frequent exposure to non-selective beta-blocker activity of timolol. 10 The purpose of this study is to compare the efficacy and cardiovascular safety of two times and three times a day administration of Cosopt eye drop in treatment naive primary open angle glaucoma eyes.
Method:
This study was conducted at the glaucoma clinic of the Labbafinejad Medical Center from September 2014 to March 2015. The study was approved by the ethics committee and the institutional review board at the Ophthalmic Research Center and followed the tenets of the Declaration of Helsinki. Informed written consent was obtained from each participant.
Patients with newly diagnosed primary open angle glaucoma who had not received any glaucoma medication were included. Exclusion criteria were: age ≤ 30, history of using glaucoma medication, past history of glaucoma surgery, any ocular or systemic condition that prohibit using timolol or dorzolamide, severe glaucoma that needed more aggressive initial IOP control, and using systemic beta blockers. Standard exercise test and a 24-hours ECG recording was carried out at the baseline using an Oxford Holter system (Oxford Instruments, Abingdon, UK), and blood pressure (BP) was measured by a cardiologist using a Baumanometer mercury sphygmomanometer (W.A. Baum Co. Inc., Copiague, New York, USA), the patient having been comfortably seated for at least 5 min.Blood pressure was also checked at the time of diurnal IOP measurements.
Patients were started on Cosopt eye drop twice a day for one month and upon their return all the baseline measurements were repeated again by the same examiners. After filling the questionnaires and recording 24 hours heart rate and BP, patients were instructed to increase from twice a day to three times a day schedule.
After one month of higher dosage therapy, all the previous examinations were performed in the same manner and data were recorded.
All measurements were taken between 9-11 am, before instillation of the morning drop of Cosopt.
The primary outcome measure was IOP and secondary measures were changes in heart rate and blood pressure.
All analyses were performed using SPSS software (SPSS Statistics for Windows, Version 25, Armonk, NY, IBM Corporation). Frequency, percent, mean±SD, median, and range were used to describe the data. The student' t test was used to measure changes in IOP, heart rate, and BP at different time points. Statistical significance was set at p< 0.05.
Results:
A total of 33 patients were enrolled in this study but only 31 patients were included in final analysis.
One patient was lost to follow-up and one patient quitted the study due to bradycardia. Both cases were excluded during the first month of treatment.
Only the eye with higher baseline IOP was included for final analysis. Mean 24h systolic blood pressure was 131±14.9 mmHg at baseline and was decreased to 128.5±15.7 after 1 month of treatment with Cosopt BID (P = 0.03). The 2-month measurement was comparable with 1-month BP reading. (Figure 3) . One case developed bradycardia 3 weeks after starting Cosopt and medication was immediately discontinued, which led to normalization of heart rate. No ocular discomfort was reported by the patients during the course of the study.
Discussion:
In the current study, Cosopt BD reduced the IOP by almost 28% from the baseline which is comparable to previous reports on its efficacy. 5, 9, 11, 12 Increasing the dose of the medication to three times a day provided further IOP reduction by 12% and delivered 40% reduction from the baseline that agrees with significant efficacy of Cosopt TDS observed in previous study. 9 This additional IOP lowering effect was not associated with any major systemic adverse effect or any change in heart rate and blood pressure.
Introduction of several classes of glaucoma medications since 1979 has rendered medical therapy as the mainstay treatment for early glaucoma cases. 13 Unfortunately, no new class of glaucoma medication has been developed since early 2000 and recent endeavors revolved around combining already existing medications to increase the efficacy and improve the compliance.
Fixed combination drugs are attractive alternative for glaucoma patients as it is shown that more than 50% of glaucoma cases need more than one drop, 14 and there is direct correlation between the number of the medication and the compliance. 15 Fixed combination drugs have at least the same efficacy as concomitant administration and they increase patient persistence and reduce the cost . The problem though is to sync the different dosage schedule of each of agents in combination. While timolol is recommended to be administered twice daily, dorzolamide needs three-times a day doses to build up to steady state levels of drug concentration in the ciliary body. 16, 17 Cosopt is recommended to be used twice daily to trade off higher dorzolamide efficacy for less timolol side effect. 7 The result of our study showed that increasing the dosage result in significant IOP reduction unparalleled to any other single or combined medication. 18 19 Furthermore, IOP controlling pattern of more frequent usage tended to have a plateau profile, which by blunting IOP fluctuations prevents further optic nerve head damage caused by undetected IOP peaks. 20 The dynamic behaviour of intraocular pressure is thoroughly studied. 21-25 26 It is demonstrated that two-third of IOP peaks occur outside office hours 25 and rise of IOP during the nocturnal period is documented in both glaucoma and normal eyes. 21, 22, 25 These undetected high IOPs are considered a reason for progressing glaucomatous optic neuropathy despite apparently well controlled IOP. In fact, 24-hours IOP reading led to a modification of clinical management in almost 80% of reviewed glaucoma patients. 27 Our findings shows that timolol significantly decreases heart beat and blood pressure at all visit points during a day. This finding is in agreement with previous reports on systemic effects of topical timolol administration [28] [29] [30] and corroborates with high bioavailability of timolol drop through conjunctival and nasal mucosa. [31] [32] [33] Also, our results confirmed findings of Moisseiev et al. and showed that higher dosage has no additional systemic beta-blockade effect . 9 Although undoubtedly higher dosage of medication expose patients to higher systemic concentration of timolol, careful patient selection and thorough review system as well as punctal occlusion and eyelid closure help to avoid undesired systemic side effects. 30 The strength of current study is its prospective nature and using 24 hours heart rate and blood pressure monitoring.
But there are limitation to this study. We did baseline comprehensive cardiology exam and would have excluded the patient if there was unusual finding, but in real practice systemic evaluation is rarely done for healthy individual and higher exposure may affect susceptible patients. Also, respiratory function test was not performed in this study, so we cannot comment on the possible respiratory side effect of higher dosage. Further, the effect of higher dosage schedule on lipid profile, central nervous system, exercise intolerance, and endocrine system was not evaluated in our study. One potential disadvantage of higher dosage schedule is the late night dosing of timolol as it may reduce ocular perfusion pressure, which is linked to progressive glaucomatous damage by some studies. 34, 35 Although we did not observe any change in blood pressure by increasing the dose of timolol, aggravated nocturnal hypotension remains a concern for administering Cosopt three times a day. Moreover, we only followed our patients for 2 months and it is possible that by longer follow up and more exposure to timolol inadvertent cardiac and respiratory side effects devople.
In conclusion, our study showed that Cosopt administered three times a day has significantly higher IOP reduction than 2-times a day schedule.
